Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $538.4 million.

  • NewAmsterdam Pharma's Cash & Equivalents rose 2736.46% to $538.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $538.4 million, marking a year-over-year increase of 2736.46%. This contributed to the annual value of $771.7 million for FY2024, which is 12668.32% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma's Cash & Equivalents is $538.4 million, which was up 2736.46% from $563.9 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Cash & Equivalents ranged from a high of $771.7 million in Q4 2024 and a low of $340.4 million during Q4 2023
  • Over the past 4 years, NewAmsterdam Pharma's median Cash & Equivalents value was $444.4 million (recorded in 2022), while the average stood at $497.6 million.
  • As far as peak fluctuations go, NewAmsterdam Pharma's Cash & Equivalents crashed by 2390.49% in 2023, and later surged by 12668.32% in 2024.
  • Quarter analysis of 4 years shows NewAmsterdam Pharma's Cash & Equivalents stood at $447.4 million in 2022, then decreased by 23.9% to $340.4 million in 2023, then soared by 126.68% to $771.7 million in 2024, then tumbled by 30.23% to $538.4 million in 2025.
  • Its Cash & Equivalents stands at $538.4 million for Q3 2025, versus $563.9 million for Q2 2025 and $748.4 million for Q1 2025.